Displaying all 858 funding opportunities ($403,130,000) that matched your search: [Only Active Grants] AND [Category: Health] AND [Sort By Due Date Soonest First]
The National Heart, Lung, and Blood Institute (NHLBI) and the National Hemophilia Foundation (NHF) invite applications for studies that will lead to improved treatment of hemophilia, von Willebrand disease, and other hereditary bleeding disorders with the ultimate goal of finding a cure for bleeding disorders. The objectives of this program are to stimulate research to improve therapy, and enhance understanding of immune response and safety issues related to novel therapeutics, gene transfer or cell based therapies for bleeding disorders.
- This Funding Opportunity Announcement (FOA) invites research applications to develop innovative instrumentation to maximize the efficiency and augment the capabilities of molecular library high throughput screening systems. Applications in response to this FOA should propose development of instrumentation suitable for integration into large high throughput screening operations and compatible with scalable approaches to chemical genomics research. This announcement is a NIH Roadmap-related activity and was developed by the Roadmap Molecular Libraries and Imaging Implementation Group. - This funding opportunity will utilize the Small Business Technology Transfer (STTR) mechanism, but will be run in parallel with a program announcement of identical scientific scope (PA-06-019) that will utilize the Small Business Innovation Research (SBIR) grant mechanism. - This funding opportunity also accompanies a Request for Applications of similar scientific intent (RFA RM-04-020) that utilized the traditional research project grant (R01) mechanism. That RFA is a component of the NIH Roadmap (http://nihroadmap.nih.gov) Molecular Libraries and Imaging Initiative. - Budgets up to $ 200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $ 400,000 total costs per year and up to 2 years may be requested for Phase II. - No funds have been specifically set aside for this program; the number of awards and the amount of funds provided for awards have not been predetermined. - Only United States SBCs are eligible to submit STTR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as ...
- This Funding Opportunity Announcement (FOA) invites research applications to develop innovative instrumentation to maximize the efficiency and augment the capabilities of molecular library high throughput screening systems. Applications in response to this FOA should propose development of instrumentation suitable for integration into large high throughput screening operations and compatible with scalable approaches to chemical genomics research. This announcement is a NIH Roadmap-related activity and was developed by the Roadmap Molecular Libraries and Imaging Implementation Group. - This FOA will utilize the Small Business Innovation Research (SBIR) grant mechanisms for Phase I, Phase II, and Fast-Track applications. - This FOA will be run in parallel with a FOA of identical scientific scope (PA-06-020) that will utilize the Small Business Technology Transfer (STTR) grant mechanism. - This funding opportunity also accompanies a Request for Applications of similar scientific intent (RFA-RM-04-020) that utilized the traditional research project grant (R01) mechanism. That RFA is a component of the NIH Roadmap (http://nihroadmap.nih.gov) Molecular Libraries and Imaging Initiative. - Budgets up to $ 200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $ 400,000 total costs per year and up to 2 years may be requested for Phase II. - No funds have been specifically set aside for this program; the number of awards and the amount of funds provided for awards have not been predetermined. Eligibility requirements are described in the SF424 (R&R) SBIR/STTR Application Guide. - Only small business concerns are eligible to submit applications. Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support, in accordance with SBIR institutional requirements. - See Section IV for application materials. ...
National Institute on Aging (NIA) seeks small business applications in specific areas to enhance the coordination and optimization of the SBIR grant program across NIA?s four programs of research: Behavioral-Social Research, Biology of Aging, Geriatrics and Clinical Gerontology, and Neuroscience and Neuropsychology of Aging.
- The National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute of Neurological Disorders and Stroke (NINDS) invite Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) for the development and delivery of novel in vivo image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy (applications may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies). - This funding opportunity is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions and treatments of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality. - Research partnerships among investigators in both academia and device and drug industries are encouraged to more rapidly translate and deliver completed imaging system developments.
The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. These AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH programs, to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale health-related research projects proposed by faculty members of eligible, domestic institutions. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. This funding opportunity will use the R15 mechanism. Eligible organizations include all public or private institutions and components of institutions such as health professional schools/colleges and other academic components of domestic institutions offering baccalaureate or advanced degrees in the sciences related to health, except those that have received research grants and/or cooperative agreements from the NIH totaling more than $3 million per year (in both direct and indirect costs) in each of four (4) or more of the last seven (7) years.
This funding opportunity provides updated guidelines for National Institutes of Health (NIH) support of conferences and scientific meetings. Because the nature and scope of the proposed activities will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number of applications, quality, duration, and costs of the applications received. This funding opportunity announcement (FOA) will use the NIH conference grant (R13) and conference cooperative agreement (U13) award mechanisms.
- The purpose of this FOA is to invite applications by small business concerns (SBC) for the commercial development of technologies for high throughput data acquisition and analysis that could aid the research fields of basic behavioral science or neuroscience relevant to the mission of the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS). - Only STTR Phase I, Phase II, and Fast Track grant applications are solicited by this FOA. - This funding opportunity will be run in parallel with a funding opportunity of identical scientific scope, ?HIGH THROUGHPUT TOOLS FOR BRAIN AND BEHAVIOR? (PA-06-023) that will utilize the Small Business Innovation Research (SBIR [R43/R44] grant mechanisms. - Budgets up to $200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $450,000 total costs per year and up to 3 years may be requested for Phase II. - No funds have been specifically set aside for this program; the number of awards and the amount of funds provided for awards have not been predetermined. - Only United States SBCs are eligible to submit STTR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III.I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. On an STTR application, the Project Director/Principal Investigator (PD/PI) may be employed with the small business concern or the participating non-profit research institution as long as he/she has a formal appointment with or commitment to the applicant small business concern, which is characterized by an official relationship
- The purpose of this FOA is to invite applications by small businesses for the commercial development of technologies for high throughput data acquisition and analysis that could aid the research fields of basic behavioral science or neuroscience relevant to the mission of the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS). - Only Small Business Innovation Research (SBIR) Phase I, Phase II, and Fast Track grant applications are solicited by this FOA. - This funding opportunity will be run in parallel with a funding opportunity of identical scientific scope, ?HIGH THROUGHPUT TOOLS FOR BRAIN AND BEHAVIOR? (PA-06-024) that will utilize the Small Business Technology Transfer (STTR [R41/R42]) grant mechanism. - Budgets up to $ 200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $ 450,000 total costs per year and up to 3 years may be requested for Phase II. - No funds have been specifically set aside for this program; the number of awards and the amount of funds provided for awards have not been predetermined. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. On an SBIR application, the Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50%) with the SBC at the time of award and for the duration of the project. - Applicant SBCs may submit more than one application, provided each application is scientifically ...
- This Funding Opportunity Announcement (FOA), issued as an initiative of the trans-NIH Bioengineering Consortium (BECON) on behalf of the participating Institutes and Centers, invites Small Business Technology Transfer (STTR) grant applications for projects for developing and applying nanotechnology to biomedicine. Nanotechnology is defined as the creation of functional materials, devices and systems through control of matter at the scale of 1 to 100 nanometers, and the exploitation of novel properties and phenomena at the same scale. Nanotechnology is emerging as a field critical for enabling essential breakthroughs that may have tremendous potential for affecting biomedicine. Moreover, nanotechnologies developed in the next several years may well form the foundation of significant commercial platforms that shift the paradigms of clinical applications. - Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. - This funding opportunity will use the STTR (R41/R42) grant mechanism. - This funding opportunity will be run in parallel with a FOA of identical scientific scope, ?Manufacturing Processes of Medical, Dental, and Biological Technologies" (PA-06-009) that will utilize the Small Business Innovation Research (SBIR [R43/R44]) grant mechanism. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as
- This FOA requests applications using the SBIR Cooperative Agreement (U44) mechanism to provide support for Phase II, and Fast-Track projects that directly address identification and pre-clinical testing of new therapeutics. - Only Aims required for therapy development can be supported in this program. No basic/mechanistic Aims may be included in the research plan. - There is no specific limit on the total funds that will be awarded under this FOA or on the number of awards. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. - This FOA employs the SBIR (U44) cooperative agreement mechanism. Applications may be submitted for support as Phase II or Fast-Track grants. Phase II applicants may request a project period of up to three years and a budget of up to $750,000 total costs per year, or $1 million total costs per year if studies required for IND or IDE filing with the FDA are included. Applicants may request a project period of up to two years and a budget of up $300,000 total costs per year for the Phase I part of a Fast-Track application. - Initial merit review is convened by the NINDS Scientific Review Branch. - Only U.S. small business concerns are eligible to submit SBIR applications. A small business concern is one that, on the date of award, meets ALL of the criteria as described in Section III. I.A. of this announcement. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. The Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50%) with the small business at the time of award and for the duration of the project, which precludes full-time employment ...
- The participating institutes of the National Institutes of Health invite the small business community to apply cutting edge-technology to develop new approaches and chemical modifications that will increase the long term stability, delivery and targeting of siRNAs in cells and tissues for laboratory and therapeutic applications. The number of awards made under this solicitation will depend on the overall scientific merit of the applications and the availability of funds. - This PA uses the STTR (R41/R42) mechanisms. - This funding opportunity will utilize the Small Business Technology Transfer (STTR) mechanism, but will be run in parallel with a program announcement of identical scientific scope (PA-06-003) that will utilize the Small Business Innovation Research (SBIR) grant mechanism. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. On an SBIR application, the Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50%) with the SBC at the time of award and for the duration of the project. - Applicant SBCs may submit more than one application, provided each application is scientifically distinct. - See Section IV.1 for application materials. The application instructions for this Funding Opportunity Announcement (FOA) are located at the following links: http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_SBIR_STTR.doc (MS Word) and http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_SBIR_STTR.pdf (PDF). Applicants are ...
- The participating institutes of the National Institutes of Health invite the small business community to apply cutting edge-technology to develop new approaches and chemical modifications that will increase the long term stability, delivery and targeting of siRNAs in cells and tissues for laboratory and therapeutic applications. - The number of awards made under this solicitation will depend on the overall scientific merit of the applications and the availability of funds. - This PA uses the SBIR mechanisms. Only small business concerns are eligible to submit applications. - This funding opportunity will utilize the Small Business Innovation Research (SBIR) mechanism, but will be run in parallel with a program announcement of identical scientific scope (PA-06-004) that will utilize the Small Business Technology Transfer (STTR) grant mechanism. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. On an SBIR application, the Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50 percent) with the SBC at the time of award and for the duration of the project. - Applicant SBCs may submit more than one application, provided each application is scientifically distinct. - See Section IV.1 for application materials. The application instructions for this Funding Opportunity Announcement (FOA) are located at the following links: http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_SBIR_STTR.doc (MS Word) ...
This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.
This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.
- This funding opportunity will utilize the Small Business Innovation Research (SBIR) mechanism, but will be run in parallel with a program announcement of identical scientific scope (RFA-DK-05-015) that will utilize the Small Business Technology Transfer (STTR) grant mechanism. - The National Institute of Diabetes, Digestive and Kidney diseases (NIDDK), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Child Health and Human development (NICHD) invite the small business community to apply cutting edge technology to investigate the development of new approaches to predict, prevent, treat, and cure type 1 Diabetes (T1D) and its complications.
This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications that propose to develop novel pharmacologic agents for brain research related to mental disorders, including research aimed at discovering new drugs for these disorders. In addition, this FOA solicits SBIR grant applications that propose to take existing, promising compounds through the next step of drug discovery and development. Finally, this FOA also encourages SBIR grant applications designed to study the effectiveness of novel interventions.
- The purpose of this Funding Opportunity Announcement (FOA) is to solicit from NICHD-supported SBIR Phase II awardees, competing continuation applications that propose to continue the process of assessing and improving devices or conducting preclinical studies of drugs or devices that ultimately require: 1) clinical evaluation, 2) approval of a Federal regulatory agency, and 3) continuing refinements to durable medical equipment (DME) designs such as cost reduction, testing for safety, durability, and reliability, and meeting or establishing standards. Such products include, but are not limited to, devices, drugs, vaccines, medical implants, etc. related to the mission of the NICHD. - Awards in response to this solicitation are expected to average in the range of $150,000 to $300,000 total costs per year for up to three years. - The anticipated number of awards will depend upon the scientific/technical merit of applications received and the availability of funds. - This FOA will utilize the Phase II Small Business Innovation Research (SBIR [R44]) grant mechanism and runs in parallel with a FOA of identical scientific intent, PA-06-029, that solicits applications under the Phase II Small Business Technology Transfer Research program (STTR [R42]) grant mechanisms.
- The purpose of this Funding Opportunity Announcement (FOA) is to solicit from NICHD-supported STTR Phase II awardees, competing continuation applications that propose to continue the process of assessing and improving devices or conducting preclinical studies of drugs or devices that ultimately require: 1) clinical evaluation, 2) approval of a Federal regulatory agency, and 3) continuing refinements to durable medical equipment (DME) designs such as cost reduction, testing for safety, durability, and reliability, and meeting or establishing standards. Such products include, but are not limited to, devices, drugs, vaccines, medical implants, etc. related to the mission of the NICHD. - Awards in response to this solicitation are expected to average in the range of $150,000 to $300,000 total costs per year for up to three years. - The anticipated number of awards will depend upon the scientific/technical merit of applications received and the availability of funds. - This FOA will utilize the Phase II Small Business Technology Transfer (STTR [R42]) grant mechanism and runs in parallel with a FOA of identical scientific intent, PA-06-030, that solicits applications under the Phase II Small Business Technology Transfer Research program (STTR [R42]) grant mechanisms.
- This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications that propose research and development of probes useful in imaging the structure and function of the brain and other parts of the nervous system, with award duration and amounts greater than those routinely allowed under the SBIR programs. Specifically this FOA solicits SBIR applications that propose research and development of probes that generate signals detectable by one or more imaging modality. Such probes should indicate the structure or function of molecules or subcellular elements of neurons or other cells of the nervous system. Of special interest are applications that propose research and development of novel probes, although significant enhancements of already existing probes are also solicited. Grant applications may propose projects that will result in probes solely intended for use in research or probes that might have clinical utility. It is expected that this initiative will require expertise from a variety of disciplines, including neuroscience, biology, chemistry, physics, engineering, biotechnology, and bioengineering. Moreover, it is anticipated that these types of expertise will be brought together in various combinations in individual proposed projects. - Budgets up to $200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $400,000 total costs per year and up to 3 years may be requested for Phase II. - No funds have been specifically set aside for this program; the number of awards and the amount of funds provided for awards have not been predetermined. - This funding opportunity will be run in parallel with a funding opportunity of identical scientific scope, ?Probes for Microimaging The Nervous System? (PA-06-022) that will utilize the Small Business Technology Transfer (STTR [R41/R42]) grant mechanisms. - Only United States SBCs are eligible to submit SBIR applications. A SBC is
